The use of the plasma concentration-effect relationship as a tool for the study of the mechanism of action of naloxone effects on mood and endocrine function

Journal of Psychopharmacology

Volumn 11, Issue 4, 1997, Pages 361-365

  Martín Del Campo, Alfonso F ^a   Granados Soto, Vinicio ^b   Aguirre Bañuelos, Patricia ^b   Cárdenas, Mario ^c   Castañeda Hernández, Gilberto ^b  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Concentration effect relationship; Endocrine function; Endogenous opioid system; Mood; Naloxone

Indexed keywords

LUTEINIZING HORMONE; NALOXONE;

ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MECHANISM; ENDOCRINE FUNCTION; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MOOD; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0030816956     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100413     Document Type: Article

References (27)

1. Belluzi J, Stein L (1977) Enkephalin may mediate euphoria and drive-reduction reward. Nature 266: 556-558
2. Bloom F, Segal D, Guillemin R, Ling N (1976) Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. Science 194: 630-632
3. Cohen M R, Cohen R M, Pickar D, Weingartner H, Murphy D L (1983) High-dose naloxone infusion to normals. Archs Gen Psychiat 43: 1037-1041
4. Dayneka N L, Garg V, Jusko W J (1993) Comparison of four models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21: 457-478
5. Dingledine R, Iversen L L, Breuker E (1978) Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. Eur J Pharmac 47: 19-27
6. File S E, Silverstone T (1981) Naloxone changes self-ratings but not performance in normal subjects. Psychopharmacology 74: 353-358
7. Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York
8. Granados-Soto V, López-Muñoz F J, Castañeda-Hernández G, Salazar L A, Villarreal J E, Flores-Murrieta F J (1992) Relationship between paracetamol plasma levels and its analgesic effect in the rat. J Pharm Pharmac 44: 741-744
9. Granados-Soto V, López-Muñoz F J, Castañeda-Hernández G, Hong E, Flores-Murrieta F J (1995) Relationship between pharmacokinetics and the analgesic effect of ketorolac in the rat. J Pharmac Exp Ther 272: 352-356
10. Grevert P, Goldstein A (1977) Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. Proc Nat Acad Sci USA 74: 1291-1294
11. Grevert P, Albert L H, Inturrisi C E, Goldstein A (1983) Effects of eight-hour naloxone infusions on human subjects. Biol Psychiat 18: 1375-1392
12. Grossman A, Rees L H (1983) The neuroendocrinology of opioid peptides. BMJ 39: 83-89
13. Hoehn-Saric R, Masek B J (1981) Effects of naloxone on normal and chronically anxious patients. Biol Psychiat 16: 1041-1045
14. Holford N H G, Sheiner L B (1981) Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429-453
15. Hughes J, Smith T W, Kosterlitz W, Fothergill L A, Morgan A B, Morris H R (1975) Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258: 577-579
16. Jaffe J H, Martin W R (1990) Opioid analgesics and antagonists. In Goodman Gilman A, Rall T W, Nies A S, Taylor P (eds) The pharmacological basis of therapeutics, 8th edn. Pergamon Press, Oxford, pp. 485-521
17. Jones R T, Herning R I (1979) Naloxone-induced mood and physiologic changes in normal volunteers. In Usdin E, Bunney W E, Kline N S (eds), Endorphins in mental health. Cambridge University Press, New York, pp. 484-491
18. Joyce P R, Donald R A (1987) Naloxone augments the hypothalamic-pituitary-adrenal axis response to methylphenidate in normal subjects. J Psychiat Res 21: 297-300
19. Jusko W J, Ko H C (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmac Ther 56: 406-419
20. Laurijssens B E, Greenblatt D J (1996) Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 30: 52-76
21. Levy G (1994) Mechanism-based pharmacodynamic modeling. Clin Pharmac Ther 56: 356-358
22. Martin del Campo A F, McMurray R G, Besse G M, Grossman A (1992) Effect of 12-hour infusion of naloxone on mood and cognition in normal male volunteers. Biol Psychiat 32: 344-353
23. Martín del Campo A F, Dowson J H, Herbert J, Paykel E S (1994) Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man. Psychopharmacology 114: 583-590
24. Mendelson J H, Ellingboe J, Keuhnle J C, Mello N K (1979) Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 3: 231-236
25. Ngai S H, Berkowitz B A, Yang J C, Hempsted J, Spector S (1976) Pharmacokinetics of naloxone in rats and in man: Basis for its potency and short duration of action. Anesthesiology 44: 398-401
26. Schwinghammer T L, Kroboth P D (1988) Basic concepts in pharmacodynamic modeling. J Clin Pharmac 28: 388-394
27. van Wimersma Greidanus T B, Grossman A B (1991) Opioid regulation of pituitary function. Prog Sens Physiol 12: 1-64